Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
35.27
-1.08 (-2.97%)
Mar 9, 2026, 3:56 PM EDT - Market open
Harrow Revenue
In the year 2025, Harrow had annual revenue of $272.30M with 36.41% growth. Harrow had revenue of $89.09M in the quarter ending December 31, 2025, with 33.31% growth.
Revenue (ttm)
$272.30M
Revenue Growth
+36.41%
P/S Ratio
4.81
Revenue / Employee
$730,035
Employees
373
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.30M | 72.69M | 36.41% |
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Perrigo Company | 4.25B |
| Phibro Animal Health | 1.46B |
| Evotec SE | 887.40M |
| ANI Pharmaceuticals | 883.37M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
HROW News
- 5 days ago - These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
- 5 days ago - Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference - GlobeNewsWire
- 5 days ago - Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) - Seeking Alpha
- 5 days ago - Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Harrow Shares Collapse, Another Opportunity? - Seeking Alpha
- 6 days ago - Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication - GlobeNewsWire
- 6 days ago - Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - GlobeNewsWire
- 19 days ago - Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 - GlobeNewsWire